Short answer
Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on August 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). No earnings figures, reporting period, or operating results included in the excerpt.
Replimune Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- No earnings figures, reporting period, or operating results included in the excerpt
Item EX-99.1 · Exhibit EX-99.1
- FDA accelerated approval makes TUDRIQEV Replimune’s first commercial product; U.S. launch expected within 60 days
- Approval covers advanced cutaneous melanoma after PD-1 progression, creating near-term commercial revenue potential
- Approval depends on confirmatory benefit; IGNYTE-3 overall-survival readout expected in 2030, creating major regulatory risk
- Cash, equivalents and short-term investments fell to $195.3M; $141.0M August financing extends operations beyond twelve months
- Fiscal Q1 net loss narrowed to $69.8M from $86.7M; R&D fell to $49.3M and SG&A to $19.0M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Replimune Group, Inc. 8-K filings
Get the next REPL 8-K as it lands
Follow REPL for push alerts, or ask the research agent what this filing means.